- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Desirudin - ...
MedChemExpress - Model Desirudin -120993-53-5
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction[1][2].MCE products for research use only. We do not sell to patients.
Desirudin
MCE China:Desirudin
Brand:MedChemExpress (MCE)
Cat. No.HY-109549
CAS:120993-53-5
Synonyms:CGP 39393; Revasc
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Description:Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction.
In Vivo:Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation[1]. Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2].
IC50 & Target:ED50: 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2]. In Vivo Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation[1]. Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED50 values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED50 values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mongrel dogs model of cardiopulmonary bypass[1]
Hot selling product:Peiminine | Marizomib | JNK-IN-7 | LLY-283 | SM 16 | Mesitaldehyde | SU 5402 | Sodium aescinate | Retinyl acetate | L-Ornithine
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. J M Walenga, et al. Evaluation of CGP 39393 as the Anticoagulant in Cardiopulmonary Bypass Operation in a Dog Model. Ann Thorac Surg. 1994 Dec;58(6):1685-9. [Content Brief]
[2]. M D Talbot, et al. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost. 1989 Feb 28;61(1):77-80. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。
